18F-FDG PET/CT for malignant small intestinal neoplasms

RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE

¹⁸F-FDG PET/CT for malignant small intestinal neoplasms

SUN Long，

ZHAO Long，

LUO Zuoming，

WEI Jihong，

SUN Yonghong，

YANG Rongshui，

WU Hua

Nuclear Science and Techniques

Vol.21, No.2

pp.94-98

Published in print 20 Apr 2010

DOI：10.13538/j.1001-8042/nst.21.94-98

37200

In this paper, ¹⁸F-FDG PET/CT data of 19 malignant SINs (small intestinal neoplasms) were consecutively reviewed. Nnine patients accepted PET/CT scan for preoperative diagnosis and staging, while ten patients presented follow-up after treatment and restaging. The results were correlated with abdomen enhanced CT and surgical pathological findings. Abdominal pain and weight loss were the most common findings. About 16% SINs located in the duodenum, 52% in the jejunum and 32% in the ileum. Lymphoma was the most frequent neoplasms. PET/CT revealed residual or recurrent malignant SINs in 5 patients who had negative or non-definite findings by abdomen CT and demonstrated extra-abdomen metastasis in 3 patients. Clinical decisions of treatment were changed for 6 patients after PET/CT examinations. The ¹⁸F-FDG PET/CT were better than CT in accuracy, negative predictive value and positive predictive value (89.5% vs 68.4%, 100% vs 66.7%, and 81.8% vs 69.2%, respectively). Whole body ¹⁸F-FDG PET/CT may be an effective molecular imaging method for staging and restaging of malignant SINs.

Malignant small intestinal neoplasmStagingRestagingMolecular imaging18F-fluorodeoxyglucosePositron emission tomography/computed tomography

References

[1]

Ripamonti C I, Easson A M, Gerdes H. Eur J Cancer, 2008, 44: 1105-1115.

[2]

Bozdag A D, Nazli O, Tansug T, et al. Hepatogastroenter-ology, 2003, 50 Suppl 2: ccxvi-ccxviii.

[3]

Talamonti M S, Goetz L H, Rao S, et al. Arch Surg, 2002, 137: 564-570, discussion 570-571.

[4]

Ito H, Perez A, Brooks D C, Osteen R T, et al. J Gastrointest Surg 2003, 7: 925-930.

[5]

Dabaja B S, Suki D, Pro B, Bonnen M, et al. Cancer, 2004, 101: 518-526.

[6]

Weissleder R. Science, 2006, 312: 1168-1171.

[7]

Hoffman J M, Gambhir S S. Radiology, 2007, 244: 39-47.

[8]

Abrahams N A, Halverson A, Fazio VW, et al. Dis Colon Rectum, 2002, 45: 1496-1502.

[9]

Ugurlu M M, Asoglu O, Potter D D, et al. J Gastrointest Surg, 2005, 9: 1182-1188.

[10]

North J H, Pack M S. Am Surg, 2000, 66: 46-51.

[11]

Agrawal S, McCarron E C, Gibbs JF, et al. Ann Surg Oncol, 2007, 14: 2263-2269.

[12]

Mosler P, Mergener K D, Brandabur J J, et al. J Clin Gastroenterol, 2005, 39: 124-128.

[13]

Jeong S H, Lee K J, Kim Y B, et al. J Gastroenterol Hepatol, 2008, 23: 51-55.

[14]

Nakamura M, Niwa Y, Ohmiya N, et al. Gan To Kagaku Ryoho, 2008, 35: 169-173.

[15]

Cobrin G M, Pittman R H, Lewis B S. Cancer, 2006, 107: 22-27.

[16]

De Franco A, Celi G, Restaino G, et al. Rays, 2002, 27: 35-50.

[17]

Nagi B, Verma V, Vaiphei K, et al. Abdom Imaging, 2001, 26: 474-480.

[18]

Sailer J, Zacherl J, Schima W. Cancer Imaging, 2007, 7: 224-233.

[19]

Schwarz M, Pauls S, Sokiranski R, et al. Am J Surg, 2001, 182: 243-249.

[20]

Fukumoto A, Tanaka S, Imagawa H, et al. Scand J Gastroenterol, 2008, 4:1-8.

[21]

Masselli G, Gualdi G. Abdom Imaging, 2008, 19. [Epub ahead of print]

[22]

Czernin J, Weber W A, Herschman H R. Annu Rev Med, 2006, 57: 99-118.

[23]

Jager P L, de Korte M A, Lub-de Hooge M N, et al. Cancer Imaging, 2005, 5: 27-32.

[24]

Langenhoff B S, Oyen W J, Jager G J, et al. J Clin Oncol, 2002, 20: 4453-4458.

[25]

Abhyankar S A, Nair N. Clin Nucl Med, 2008, 33: 213-214.

[26]

Smithers B M, Couper G C, Thomas J M, et al. Dis Esophagus, 2008, 21: 151-158.

[27]

Sun L, Ye H Y, Zhang Y H, et al. World J Gastroenterol, 2007, 13: 6115-6118.

[28]

Fang Y H, Muzic R F. J Nucl Med, 2008, 49: 606-614.

[29]

Meave A, Soto M E, Reyes P A, et al. Tex Heart Inst J, 2007, 34: 466-469.

[30]

Kao P F, Chou Y H, Lai C W. Clin Nucl Med, 2008, 33: 308-310.